Holdings
46
Concentrated
Top 10 weight
43%
Concentration
Strategy data
N/A
Not reported
Equity
96%
Asset allocation
Portfolio
4Sectors
2Large positions
69.5%Top: Pharmaceuticals & Biotechnology
0.0%Cash
Market-cap allocation
Large cap25%
Mid cap23%
Small cap46%
Asset allocation
Equity96%
Top holdings
8.7%
5.6%
EQ - AJANTA PHARMA LTD.EQUITY
4.8%4.0%
EQ - LUPIN LTD.EQUITY
3.6%EQ - GLAND PHARMA LTD.EQUITY
3.6%3.5%
3.1%
3.1%
NET CURRENT ASSETSDERIVATIVE
2.9%EQ- GLOBAL HEALTH LTD.EQUITY
2.8%2.8%
2.7%
2.6%
2.5%
2.4%
2.3%
2.2%
2.2%
2.2%
2.2%
2.1%
2.0%
1.9%
1.8%
1.7%
1.7%
1.6%
EQ - CIPLA LTD.EQUITY
1.6%EQ - BIOCON LTD.EQUITY
1.6%1.3%
1.3%
EQ - PFIZER LIMITEDEQUITY
1.2%EQ - WINDLAS BIOTEC LTDEQUITY
1.2%1.2%
1.1%
1.0%
0.99%
EQ - MANIPAL HEALTH ENTERPRISES LIMITEDDERIVATIVE
0.91%0.81%
0.81%
0.73%
EQ - ORCHID PHARMA LTD.EQUITY
0.73%0.61%
0.46%
0.02%
AI Smart summary
Portfolio read
- 96% equity.
- 46 disclosed positions across 4 classified equity sectors.
- Largest equity sector is Pharmaceuticals & Biotechnology at 69.5% of the portfolio.
Watchpoints
- Small-cap exposure is 46%, which may increase volatility and liquidity risk.
- Sector concentration is elevated: Pharmaceuticals & Biotechnology represents 69%.
Auto-generated from fund metrics. Educational only - not investment advice.
Peer comparison
Other funds in Sectoral / Thematic.
HDFC Manufacturing fund91 holdings · 34% top 10 · 80% AS
UTI Quant Fund89 holdings · 36% top 10
Icici Prudential Energy Opportunities Fund88 holdings · 43% top 10 · 83% AS
ICICI Prudential Business Cycle Fund86 holdings · 50% top 10 · 70% AS
Edelweiss Technology Fund84 holdings · 54% top 10
Axis Business Cycles Fund81 holdings · 29% top 10 · 67% AS
Sector exposure
Full industry / sector breakdown aggregated from the fund's holdings.
69.5%
24.0%
1.7%
1.0%